Cryoballoon Versus Radiofrequency Ablation for Persistent Atrial Fibrillation: Meta‐Analysis of Randomized Trials
Pacing and Clinical Electrophysiology · 2026-11 · 49 (11) · 1692-1705
DOI: 10.1111/pace.70350 ↗At a glance
Metaanalyse in Pacing and Clinical Electrophysiology, published online on 2026-07-03. Written by Harroop Bola and 8 co-authors. Institution: Faculty of Medicine, Imperial College London, England, London, UK. Major MEDLINE topics: Atrial Fibrillation, Cryosurgery, Catheter Ablation. 54 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
Pulmonary vein isolation (PVI) alone achieves modest arrhythmia freedom in persistent atrial fibrillation (PeAF). Cryoballoon ablation (CBA) offers a single‐shot alternative to radiofrequency ablation (RFA) that streamlines procedural workflow. We aimed to quantify the clinical efficacy, procedural efficiency, and safety of CBA versus RFA through a meta‐analysis of randomized controlled trials (RCTs). Methods and Results Systematic review of PubMed, Embase, and Scopus identified 5 RCTs enrolling 1,091 patients (515 CBA, 576 RFA). The primary endpoint was 12‐month freedom from any atrial arrhythmia, with isolated AF, and atrial tachycardia/flutter evaluated as secondary endpoints. Random‐effects models generated relative risks (RRs) and mean differences (MDs) with 95% confidence intervals (CI). Time‐to‐event data were pooled using a generic inverse‐variance approach to derive hazard ratios (HR). CBA and RFA demonstrated equivalent freedom from any arrhythmia (RR 0.97, 95% CI 0.81–1.15; p = 0.71). Time‐to‐event analysis corroborated a comparable recurrence hazard (HR 0.91, 95% CI 0.67–1.24; p = 0.56; I 2 = 0%). Repeat ablation rates were identical (RR 0.93; p = 0.50). CBA significantly reduced procedural time (MD −45.37 min; p < 0.0001), while major complications were comparable (1.5% vs. 2.7%; p = 0.18). Trial sequential analysis indicated that further randomization is unlikely to demonstrate superiority.
Conclusion
In PeAF, CBA and RFA achieve equivalent 12‐month arrhythmia‐free survival and comparable repeat‐ablation rates, while CBA confers a highly significant reduction in procedural time. However, reliance on 12‐month follow‐up and heterogeneous rhythm surveillance protocols may limit assessments of true long‐term durability.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Faculty of Medicine, Imperial College London, England, London, UK.
- London Northwest Healthcare NHS Trust, England, London, UK.
- Department of Internal Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Chelsea and Westminster Hospital NHS Foundation Trust, England, London, UK.
- National Heart and Lung Institute, Imperial College London, England, London, UK.
- Department of Cardiology, Imperial College Healthcare NHS Trust, England, London, UK.
ORCID profiles: Harroop Bola, Aksaan Arif, Joshua J Hon
Cite
APA
Bola, H., Arif, A., J Hon, J., Giritharan, G., Khandelwal, P., Avakian, R., Rai, A., Patel, K. H. K., & Ng, F. S. (2026). Cryoballoon Versus Radiofrequency Ablation for Persistent Atrial Fibrillation: Meta‐Analysis of Randomized Trials. Pacing and Clinical Electrophysiology, 49(11), 1692-1705. https://doi.org/10.1111/pace.70350
Vancouver
Bola H, Arif A, J Hon J, Giritharan G, Khandelwal P, Avakian R, et al. Cryoballoon Versus Radiofrequency Ablation for Persistent Atrial Fibrillation: Meta‐Analysis of Randomized Trials. Pacing and Clinical Electrophysiology. 2026;49(11):1692-1705. doi:10.1111/pace.70350
BibTeX
@article{Bola2026,
author = {Bola, Harroop and Arif, Aksaan and J Hon, Joshua and Giritharan, Gayathri and Khandelwal, Prachur and Avakian, Rodrick and Rai, Amar and Patel, Kiran Haresh Kumar and Ng, Fu Siong},
title = {Cryoballoon Versus Radiofrequency Ablation for Persistent Atrial Fibrillation: Meta‐Analysis of Randomized Trials},
journal = {Pacing and Clinical Electrophysiology},
year = {2026},
volume = {49},
number = {11},
pages = {1692--1705},
doi = {10.1111/pace.70350}
}
EUVIMED